Drugs / BIFICO
last change Sep 2016 re-read 2 minutes ago

BIFICO

Developed for
intestinal dysmotility syndrome
Investigated by
Jinling Hospital, China

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02844426 Sep 2015 → Jun 2016 intestinal dysmotility syndrome Jinling Hospital, China Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BIFICO “patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .” NCT02844426
Known as bifid triple viable capsule ClinicalTrials.gov intervention name — accepted as the source's own label NCT02844426